Kyowa Kirin Co.,Ltd. Logo

Kyowa Kirin Co.,Ltd.

Develops antibody medicines for oncology, nephrology, immunology, and allergy.

4151 | T

Overview

Corporate Details

ISIN(s):
JP3256000005
LEI:
Country:
Japan
Address:
千代田区大手町一丁目9番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kyowa Kirin is a global specialty pharmaceutical company dedicated to addressing unmet medical needs through innovative drug discovery. The company engages in the research, development, manufacturing, and commercialization of pharmaceuticals and biotechnology products. Focusing on core therapeutic areas such as nephrology, oncology, immunology, and allergy, Kyowa Kirin leverages its advanced antibody technologies to create novel medicines. Guided by its mission of "Commitment to Life," the organization strives to deliver life-changing value to patients, their families, and medical professionals worldwide by developing and marketing innovative prescription drugs that contribute to global health and well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-31 08:30
Interim Report
半期報告書-第103期(2025/01/01-2025/12/31)
Japanese 991.7 KB
2025-07-31 08:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-07-11 09:30
Regulatory News Service
臨時報告書
Japanese 21.2 KB
2025-03-21 06:47
Registration Form
訂正有価証券届出書(参照方式)
Japanese 46.5 KB
2025-03-21 06:41
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB
2025-03-19 07:51
Registration Form
有価証券届出書(参照方式)
Japanese 56.3 KB
2025-03-11 07:31
Annual Report
有価証券報告書-第102期(2024/01/01-2024/12/31)
Japanese 4.0 MB
2025-03-11 07:31
Governance Information
内部統制報告書-第102期(2024/01/01-2024/12/31)
Japanese 22.5 KB
2025-03-11 07:31
Registration Form
確認書
Japanese 8.2 KB
2024-11-14 07:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.6 KB
2024-10-31 07:30
Board/Management Information
臨時報告書
Japanese 26.1 KB
2024-10-11 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-09-12 08:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2024-08-09 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.1 KB
2024-08-01 08:31
Interim Report
半期報告書-第102期(2024/01/01-2024/12/31)
Japanese 916.7 KB

Automate Your Workflow. Get a real-time feed of all Kyowa Kirin Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kyowa Kirin Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kyowa Kirin Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America
NEO
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America
950220
NEONC TECHNOLOGIES HOLDINGS, INC. Logo
Developing intranasal drug delivery to treat brain cancer & CNS diseases by crossing the BBB.
United States of America
NTHI
Neumora Therapeutics, Inc. Logo
Developing data-driven precision medicines for neuropsychiatric and neurodegenerative disorders.
United States of America
NMRA
Neuphoria Therapeutics Inc. Logo
Develops novel ion channel modulators for treating neuropsychiatric disorders like anxiety & PTSD.
United States of America
NEUP
NEUROCRINE BIOSCIENCES INC Logo
Develops therapies for neurological, neuroendocrine, and neuropsychiatric disorders.
United States of America
NBIX
Neurogene Inc. Logo
Developing genetic medicines using gene therapy for rare and devastating neurological diseases.
United States of America
NGNE
NeuroSense Therapeutics Ltd. Logo
Developing combination therapies for neurodegenerative diseases, with a focus on ALS.
United States of America
NRSN
NewAmsterdam Pharma Co N.V. Logo
Developing oral LDL-lowering therapies for high-risk cardiovascular disease patients.
United States of America
NAMS
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden
NEWBRY

Talk to a Data Expert

Have a question? We'll get back to you promptly.